Posted by Michael Wonder on 16 Aug 2024
US FDA accepts for priority review Deciphera’s new drug application for vimseltinib for the treatment of patients with tenosynovial giant cell tumour
15 August 2024 - The US FDA has assigned a target action date of 17 February 2025.
Ono Pharmaceutical today announced that the US FDA accepted a priority review for the new drug application on 14 August time for vimseltinib, a colony stimulating factor 1 receptor (CSF1R), for the treatment of patients with tenosynovial giant cell tumour, which is under development by Deciphera Pharmaceuticals.
